Viking Therapeutics (VKTX) reported late Wednesday a Q1 net loss of $0.41 per diluted share, compared with a loss of $0.26 a year earlier.
Analysts polled by FactSet expected a loss of $0.33.
No revenue was reported for the quarter ended March 31. The company held cash, cash equivalents, and short-term investments of $851.9 million at March 31, compared with $902.6 million on December 31, 2024.
The company's shares were down more than 1% in recent after-market activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.